FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Ongoing Phase 1/2 Clinical Trial In Patients With Diabetic Foot Ulcers

FibroBiologics, Inc.

FibroBiologics, Inc.

FBLG

0.00

Company expects existing supply will suffice to complete clinical trial and lead to cost savings

HOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs).

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.